Silodosin Capsule
Product Images NDC 72162-2446

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Silodosin (NDC 72162-2446). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (0fdaf6c9 C861 4894 B4a9 2f6a281998c1 01)

Chemical structure diagram of silodosin, the active ingredient in SILODOSIN 4 mg oral capsules. The structure includes various functional groups including amide, ether, and hydroxyl groups, representing the molecular configuration of silodosin.*

FDA Label Image

Image (0fdaf6c9 C861 4894 B4a9 2f6a281998c1 02)

A line graph depicting silodosin concentration (ng/mL) over time (hours). The plot shows an initial rise in concentration reaching a peak around 2-4 hours, followed by a gradual decline, with error bars indicating variability at each time point.*

FDA Label Image

Image (0fdaf6c9 C861 4894 B4a9 2f6a281998c1 03)

A line graph comparing change from baseline in IPSS total score over days between placebo and Silodosin Capsules 8 mg groups. The x-axis represents days (B, 3.5, 7, 14, 28, 84/LOCF) and the y-axis shows the change from baseline scores. Silodosin shows a greater decrease in IPSS score than placebo, with statistical significance indicated.*

FDA Label Image

Image (0fdaf6c9 C861 4894 B4a9 2f6a281998c1 04)

A line graph comparing the change from baseline in IPSS Total Score over time between placebo and Silodosin Capsules 8 mg groups. The x-axis represents days (Baseline, 3.5, 7, 14, 28, 84/LOCF), and the y-axis shows the change in score. Silodosin shows a greater decrease than placebo throughout the period, with statistical significance indicated by p-values.*

FDA Label Image

Image (0fdaf6c9 C861 4894 B4a9 2f6a281998c1 05)

A line graph comparing the change from baseline in Qmax (mL/sec) over days for placebo and Silodosin Capsules 8 mg. The graph tracks values at baseline, day 1, day 7, day 14, day 28, and day 84, showing a higher increase in Qmax for Silodosin compared to placebo with noted statistical significance (p<0.05).*

FDA Label Image

Image (0fdaf6c9 C861 4894 B4a9 2f6a281998c1 06)

A line graph depicting change from baseline in Qmax (mL/sec) over time (days) comparing Placebo to Silodosin Capsules 8 mg. The x-axis shows days from baseline, including 1, 7, 14, 28, and 84/Last Observation Carried Forward (LOCF). The y-axis shows change from baseline in Qmax, ranging from 0 to 4 mL/sec. Silodosin shows consistently higher Qmax changes over time compared to placebo, with statistically significant difference at day 84 (p<0.05).*

FDA Label Image

Label (Lbl721622446)

Label for Silodosin Capsules 4 mg, oral dosage form, containing 30 capsules. The label shows the NDC 72162-2446-3 and states the medication is prescription only. It is relabeled by Bryant Ranch Prepack, Inc. and manufactured by V-Ensure Pharma Technologies Pvt. Ltd. Storage instructions and packaging warnings about child resistance and moisture protection are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.